Literature DB >> 10395698

Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis.

E Quattrocchi1, M Walmsley, K Browne, R O Williams, L Marinova-Mutafchieva, W Buurman, D M Butler, M Feldmann.   

Abstract

Collagen-induced arthritis (CIA) is an experimental model of arthritis widely used to dissect the pathogenesis of human rheumatoid arthritis and to identify potential therapeutic targets. Among these, TNF-alpha has been recognized to play an important role. Here we investigate the feasibility and therapeutic efficacy of prolonged blockade of TNF-alpha activity through the adenovirus-mediated gene delivery of a dimeric chimeric human p55 TNFR-IgG fusion protein and compare it to protein therapy in established CIA. A single i.v. administration of the replication-deficient adenovirus yielded microgram serum levels of the chimeric fusion protein and ameliorated CIA for 10 days. Subsequently, benefit was lost and a rebound to greater inflammatory activity was observed despite the continual presence of bioactive TNFR fusion protein. A similar trend was also observed in mice injected directly with comparable amounts of a human TNFR-IgG fusion protein, whereas the administration of a control adenovirus-encoding beta-galactosidase or of a control human IgG1 protein did not significantly affect the disease course. The mechanisms of the rebound of CIA were investigated, and augmented Ab response to collagen type II and TNFR were identified as potential causes. Our results confirm the feasibility of adenovirus-mediated gene delivery of cytokine inhibitors in animal models of autoimmune diseases for investigational purposes and highlight the importance of prolonged studies. Further investigations are needed to optimize ways of exploiting the potential of adenoviral gene therapy in RA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395698

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 2.  Gene therapy for autoimmune disorders.

Authors:  C H Evans; S C Ghivizzani; T J Oligino; P D Robbins
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

3.  Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice.

Authors:  P Mukherjee; S-Y Yang; B Wu; Z Song; L K Myers; P D Robbins; P H Wooley
Journal:  Ann Rheum Dis       Date:  2005-04-28       Impact factor: 19.103

4.  The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis.

Authors:  K A Bush; B W Kirkham; J S Walker
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 5.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

6.  TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis.

Authors:  P Mukherjee; B Wu; L Mayton; S-H Kim; P D Robbins; P H Wooley
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

7.  Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent.

Authors:  J Adriaansen; M Khoury; C J de Cortie; F J Fallaux; P Bigey; D Scherman; D J Gould; Y Chernajovsky; F Apparailly; C Jorgensen; M J B M Vervoordeldonk; P P Tak
Journal:  Ann Rheum Dis       Date:  2007-03-15       Impact factor: 19.103

8.  Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance.

Authors:  Saba Alzabin; Philip Kong; Mino Medghalchi; Andrew Palfreeman; Richard Williams; Sandra Sacre
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156

Review 9.  Gene therapy for rheumatoid arthritis.

Authors:  E Gouze; S C Ghivizzani; P D Robbins; C H Evans
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

Review 10.  Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity.

Authors:  Hugh McDevitt; Sibyl Munson; Rachel Ettinger; Ava Wu
Journal:  Arthritis Res       Date:  2002-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.